Revumenib (SNDX-5613)

AbMole BioScience

Revumenib (SNDX-5613)

9

2169919-21-3

Chemical

Research Use Only

C32H47FN6O4S

630.82

Revumenib (SNDX-5613) is a first-in-class, effective and selective Menin-MLL binding inhibitor with Ki of 0.15 nM. Revumenib (SNDX-5613) can be used to study MLL gene rearrangement in acute leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

CCN(C(C)C)C(=O)C1=C(OC2=CN=CN=C2N3CC4(CCN(CC4)CC5CCC(CC5)N[S](=O)(=O)CC)C3)C=CC(=C1)F

12352200